The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells

Clinical Cancer Research

Volumn 15, Issue 15, 2009, Pages 4885-4894

  Milligan, Shawn A ^a,b   Burke, Patrick ^a   Coleman, David T ^a   Bigelow, Rebecca L ^a   Steffan, Joshua J ^a   Carroll, Jennifer L ^a,b   Williams, Briana Jill ^a,b   Cardelli, James A ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIGALLOCATECHIN GALLATE; ERLOTINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; SCATTER FACTOR RECEPTOR;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SCID MOUSE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68049118826     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0109     Document Type: Article

References (41)

1. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181 (Pubitemid 46316032)
2. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in nonsmall- cell lung cancer. J Clin Oncol 2007;25: 587-595 (Pubitemid 350002967)
3. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 2007;96: 857-863
4. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinibhydrochl oride (OSI- 774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899 (Pubitemid 46300205)
5. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinibin combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545-1552 (Pubitemid 46733081)
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinibin previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132 (Pubitemid 41058344)
7. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-2899
8. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-1488 (Pubitemid 40270177)
9. Cheng TL, Chang MY, Huang SY, et al. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest 2005;128:1453-1460
10. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26. (Pubitemid 40732764)
11. Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-2088 (Pubitemid 46424226)
12. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinibresistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043 (Pubitemid 46799492)
13. Huang PH, Mukasa A, Bonavia R, et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A 2007;104:12867-12872 (Pubitemid 47255246)
14. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-290 (Pubitemid 47574858)
15. Lambert JD, Hong J, Yang GY, Liao J, Yang CS. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr 2005;81:284-91S.
16. Hou Z, Lambert JD, Chin KV, Yang CS. Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention. Mutat Res 2004;555:3-19. (Pubitemid 39345394)
17. Manson MM. Inhibition of survival signalling by dietary polyphenols and indole-3-carbinol. Eur J Cancer 2005;41:1842-1853
18. Adachi S, Nagao T, Ingolfsson HI, et al. The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res 2007;67: 6493-6501 (Pubitemid 47037535)
19. Adhami VM,Malik A, Zaman N, et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007;13:1611-1619 (Pubitemid 46450454)
20. Nihal M, Ahmad N, Mukhtar H, Wood GS. Antiproliferative and proapoptotic effects of (-)-epigallocatechin- 3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 2005;114:513-521 (Pubitemid 40349609)
21. Bettuzzi S, Brausi M, Rizzi F, Castegnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234-1240 (Pubitemid 43165995)
22. McLarty J, Bigelow R, Smith M, et al. Tea polyphenols decrease serum prostate specific antigen, hepatocyte growth factors, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial factor in vitro. Cancer Prevention Res 2009, published online June 19.
23. Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009.
24. Sadava D, Whitlock E, Kane SE. The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drugresistant lung cancer cells. Biochem Biophys Res Commun 2007;360:233-237 (Pubitemid 46994711)
25. Suganuma M, Kurusu M, Suzuki K, Tasaki E, Fujiki H. Green tea polyphenol stimulates cancer preventive effects of celecoxibi n human lung cancer cells by upregulation of GADD153 gene. Int J Cancer 2006;119:33-40.
26. Balko JM, Potti A, Saunders C, Stromberg A, Haura EB, Black EP. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics 2006;7:289. (Pubitemid 44823100)
27. Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinibin lung cancer patients. Clin Cancer Res 2005;11:8686-8698 (Pubitemid 43005918)
28. Helfrich BA, Raben D, Varella-Garcia M, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 2006;12:7117-7125 (Pubitemid 44974512)
29. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65:9455-9462 (Pubitemid 41508014)
30. Nguyen HT, Adam RM, Bride SH, Park JM, Peters CA, Freeman MR. Cyclic stretch activates p38 SAPK2-, ErbB2-, and AT1-dependent signaling in bladder smooth muscle cells. Am J Physiol Cell Physiol 2000;279:C1155-67.
31. Bigelow RL, Cardelli JA. The green tea catechins, (-)-Epigallocatechin-3- gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene 2006;25:1922-1930.
32. Yu Z, Boggon TJ, Kobayashi S, et al. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res 2007;67:10417-10427 (Pubitemid 350070817)
33. de La Motte Rouge T, Galluzzi L, Olaussen KA, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007;67:6253-6262 (Pubitemid 47037507)
34. Guo A, Villen J, Kornhauser J, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008;105:692-697 (Pubitemid 351171770)
35. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinibor erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-20937
36. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-7670 (Pubitemid 40741028)
37. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006; 12:3657-3660 (Pubitemid 44000247)
38. Tang Z, Du R, Jiang S, et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFRmediated erlotinib-resistant lung cancer. Br J Cancer 2008;99:911-922
39. Zhang X, Zhang H, Tighiouart M, et al. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 2008;123:1005-1014
40. Pike LJ. Lipid rafts: bringing order to chaos. J Lipid Res 2003;44:655-667
41. Le Roy C,Wrana JL. Clathrin- and non-clathrinmediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 2005;6:112-126